Target Formulation Per SKU's

PRESCRIPTION GENERATION MATRIX PER TERRITORY RELEAF TAB (P4.
20)
Month 1 1 Month 2 1 1 Month 3 1 1 1 Month 4 1 1 1 1 Month 5 1 1 1 1 1 Month 6 1 1 1 1 1 1 Month 7 1 1 1 1 1 1 1 Month 8 1 1 1 1 1 1 1 1 Month 9 1 1 1 1 1 1 1 1 1 Month 10 1 1 1 1 1 1 1 1 1 1 Month 11 1 1 1 1 1 1 1 1 1 1 1 Month 12 1 1 1 1 1 1 1 1 1 1 1 1
FY Treatments
12 11 10 9 8 7 6 5 4 3 2 1 78
MD 1 MD 2
MD 3
14
Cum. equiv. new patients Equiv. treatment months Equiv. cumulative tablets Equiv. cumulative. boxes
2 3 540 5
3 6 1,080 11
4 10 1,800 18
5 15 2,700 27
6 21 3,780 38
7 28 5,040 50
8 36 6,480 65
9 45 8,100 81
10 55 9,900 99
11 66 11,880 119
12 78 14,040 140 58,968.00
Working objectives: URINARY STONES Working objectives: 1. One (1) out of 40 Target MD's shall respond with one (1) RELEAF 250MG Tablet prescription every month 2. One (1) new prescriptions shall be generated per month with patient consumption of 180 tablets per month 3. Total MD output is equivalent to cumulative 12 new patients the whole year 4. Constant prescription output from the original one (1) out of 40 Target MD's for RELEAF 250 Mg Tablet 5. The condition is constant requiring regular treatment with no follow up MD consultation 6. Matrix calculation sums up to total of 78 treatment months equivalent to 14,040tablets consumption the whole year 78 Treatment Months( from 12 Patients) x 180 Tablets Per Month Per Patient 14,040 Tablets Consumed in Territory Converted In Boxes of 100's 140 Boxes of RELEAF 250 MG Tablets
1 MDS = 1 RX @ 90 TABS OF RELEAF 250MG QUADRANT 1 Suller, Peter Clifford Yrastorza, Sammuel Meris, Earl QUADRANT 2 QUADRANT 3 QUADRANT 4 Maniego, Sammy
Anover, Benedict
8 Treatment Months( from 12 Patients) x 180 Tablets Per Month Per Patient
4,040 Tablets Consumed in Territory Converted In Boxes of 100's
40 Boxes of RELEAF 250 MG Tablets
PRESCRIPTION GENERATION MATRIX PER TERRITORY RELEAF FORTE(P7.25)

FY Treatments
108 99 90 81 72 63 54 45 36 27 18 9 702
MD 1 TO 3 MD 4 TO 6
MD 7 TO 9
636
Cum. equiv. new patients Equiv. treatment months Equiv. cumulative tablets Equiv. cumulative. boxes
18 27 810 58
27 54 1,620 116
36 90 16,200 270
45 135 24,300 405
54 189 34,020 567
63 252 45,360 756
72 324 58,320 972
81 405 72,900 1,215
90 495 89,100 1,485
99 594 106,920 1,782
108 702 126,360 2,106
916,110.00
Working objectives: URINARY STONES Working objectives: 1. Two (3) out of 40 Target MD's shall respond with two (3) RELEAF 500MG Tablet prescription every month 2. Nine (9) new prescriptions shall be generated per month with patient consumption of 180 tablets per month 3. Total MD output is equivalent to cumulative 108 new patients the whole year 4. Constant prescription output from the original three (3) out of 40 Target MD's for RELEAF 500 Mg Tablet 5. The condition is constant requiring regular treatment with no follow up MD consultation 6. Matrix calculation sums up to total of 702 treatment months equivalent to 126,360 tabletS consumption the whole year 702 Treatment Months( from 81 Patients) x 180 Tablets Per Month Per Patient 126,360 Tablets Consumed in Territory Converted In Boxes of 60's 2,106 Boxes of RELEAF 500 MG Tablets
3 MDS = 3 RX @ 90 TABS OF RE-LEAF FORTE QUADRANT 1 QUADRANT 2 CUARESMA, RONAN SAMANIEGO, ARLETTE QUADRANT 3 DESCARGAR, IRENE DUMLAO, JIMMY QUADRANT 4 GONZALES RICARDO TAGUBA CHRISTOPHER
BAYANI, WILHELMINA CURAMMENG, LOUISE DOMINGO, ARIEL
2 Treatment Months( from 81 Patients) x 180 Tablets Per Month Per Patient
6,360 Tablets Consumed in Territory Converted In Boxes of 60's
06 Boxes of RELEAF 500 MG Tablets
PRESCRIPTION GENERATION MATRIX PER TERRITORY APLOSYN 10 Cream 5MG (P112)

FY Treatments
72 66 60 54 48 42 36 30 24 18 12 6 468
440
Cum. equiv. new patients Equivalent day therapy Equiv. cumulative tubes Equiv. Cumulative tubes
12 18 18 18
18 36 36 36
24 60 60 60
30 90 90 90
36 126 126 126
42 168 168 168
48 216 216 216
54 270 270 270
60 330 330 330
66 396 396 396
72 468 468 468 52,416
Working objectives: 1. Three (3) out of 40 Target MD's shall respond with one( 1) APLOSYN 10 CREAM prescription every month 2. Six (6) new prescriptions shall be generated per month with patient consumption of 1 tube per month 3. Total MD output is equivalent to cumulative 72 new patient therapies the whole year 4. Rotating prescription output each month from at least one (1) out of 40 Target MD's for Aplosyn 10 C 5. The condition is intermittent requiring new prescriptions for new patient therapy each month 6. Matrix calculation sums up to total of 1 month therapies equivalent to 468 consumption the whole year 468 Treatment Months( from 81 Patients) x 1 tube Per Therapy Per Patient 468 tubes Consumed in Territory Converted In Boxes of 1's 468 tubes of Aplosyn 10 Cream
6 MDS = 1 RX/mos @1 tube/rx QUADRANT 1 MD 1 to 6 Curammeng, Louise Valdez, Ma. Febes QUADRANT 2 Chuca, Lea QUADRANT 3 QUADRANT 4 Molina, Marisol Dobles, Marianne Meris, Earl MD 7 to 12 Zosa, Mae Angelene Babiera, Tito Jr. Neri, Milagros Gil, Mendoza Catequista, Azucena Garcia, Albert
reatment Months( from 81 Patients) x 1 tube Per Therapy Per Patient
468 tubes Consumed in Territory Converted In Boxes of 1's 468 tubes of Aplosyn 10 Cream
PRESCRIPTION GENERATION MATRIX PER TERRITORY APLOSYN 10 Ointment 5MG (P112)

FY Treatments
72 66 60 54 48 42 36 30 24 18 12 6 468
359
12 18 18 18
18 36 36 36
24 60 60 60
30 90 90 90
36 126 126 126
42 168 168 168
48 216 216 216
54 270 270 270
60 330 330 330
66 396 396 396
72 468 468 468 52,416
Working objectives: 1. Three (3) out of 40 Target MD's shall respond with one( 1) APLOSYN 10 ointment prescription every month 2. Six (6) new prescriptions shall be generated per month with patient consumption of 1 tube per month 3. Total MD output is equivalent to cumulative 72 new patient therapies the whole year 4. Rotating prescription output each month from at least one (1) out of 40 Target MD's for Aplosyn 10 ointment 5. The condition is intermittent requiring new prescriptions for new patient therapy each month 6. Matrix calculation sums up to total of 1month therapies equivalent to 468 tubes consumption the whole year 468 Treatment Months( from 81 Patients) x 1 tube Per Therapy Per Patient 468 tubes Consumed in Territory Converted In Boxes of 1's 468 tubes of Aplosyn 10 ointment
468 tubes Consumed in Territory Converted In Boxes of 1's
468 tubes of Aplosyn 10 ointment
PRESCRIPTION GENERATION MATRIX PER TERRITORY APLOSYN 10-N CREAM (P124)

FY Treatments
72 66 60 54 48 42 36 30 24 18 12 6 468
369
12 18 18 18
18 36 36 36
24 60 60 60
30 90 90 90
36 126 126 126
42 168 168 168
48 216 216 216
54 270 270 270
60 330 330 330
66 396 396 396
72 468 468 468 52,416
Working objectives: 1. Three (3) out of 40 Target MD's shall respond with one( 1) APLOSYN 10- N prescription every month 2. Six (6) new prescriptions shall be generated per month with patient consumption of 1 tube per month 3. Total MD output is equivalent to cumulative 72 new patient therapies the whole year 4. Rotating prescription output each month from at least one (1) out of 40 Target MD's for Aplosyn 10 N ointment 5. The condition is intermittent requiring new prescriptions for new patient therapy each month 6. Matrix calculation sums up to total of 1month therapies equivalent to 468 tubes consumption the whole year 468 Treatment Months( from 81 Patients) x 1 tube Per Therapy Per Patient 468 tubes Consumed in Territory Converted In Boxes of 1's 468 tubes of Aplosyn 10 N C
468 tubes Consumed in Territory Converted In Boxes of 1's 468 tubes of Aplosyn 10 N C
PRESCRIPTION GENERATION MATRIX PER TERRITORY APLOSYN 25 CREAM (P124)

FY Treatments
25 22 20 18 16 14 12 10 8 6 4 2 157
136
4 6 6 6
6 12 12 12
8 20 20 20
10 30 30 30
12 42 42 42
14 56 56 56
16 72 72 72
18 90 90 90
20 110 110 110
22 132 132 132
24 157 157 157 17,584
Working objectives: 1. Two (2) out of 40 Target MD's shall respond with one( 1) APLOSYN 10 CREAM prescription every month 2. Two (2) new prescriptions shall be generated per month with patient consumption of 24 tubes per month 3. Total MD output is equivalent to cumulative 24 new patient therapies the whole year 4. Rotating prescription output each month from at least one (1) out of 40 Target MD's for Aplosyn 25 cream 5. The condition is intermittent requiring new prescriptions for new patient therapy each month 6. Matrix calculation sums up to total of 1month therapies equivalent to 157 tubes consumption the whole year 157 Treatment Months( from 24 Patients) x 1 tube Per Therapy Per Patient 157 tubes Consumed in Territory Converted In Boxes of 1's 157 tubes of Aplosyn 25 Cream
2 MDS = 1 RX/mos @1 tube/rx QUADRANT 1 MD 1 MD 2 QUADRANT 2 QUADRANT 3 Babiera Jr., Tito Garcia, Albert QUADRANT 4
157 tubes Consumed in Territory Converted In Boxes of 1's 157 tubes of Aplosyn 25 Cream
PRESCRIPTION GENERATION MATRIX PER TERRITORY APLOSYN 25 Ointment(P124)

FY Treatments
72 66 60 54 48 42 36 30 24 18 12 6 468
448
12 18 18 18
18 36 36 36
24 60 60 60
30 90 90 90
36 126 126 126
42 168 168 168
48 216 216 216
54 270 270 270
60 330 330 330
66 396 396 396
72 468 468 468 52,416
Working objectives: 1. Three (3) out of 40 Target MD's shall respond with one( 1) APLOSYN Ointment Tablet prescription every month 2. Six (6) new prescriptions shall be generated per month with patient consumption of 72 tubes per month 3. Total MD output is equivalent to cumulative 72 new patient therapies the whole year 4. Rotating prescription output each month from at least one (1) out of 40 Target MD's for Aplosyn 25 ointment 5. The condition is intermittent requiring new prescriptions for new patient therapy each month 6. Matrix calculation sums up to total of 1month therapies equivalent to 468 tubes consumption the whole year 72 Treatment Months( from 72 Patients) x 1 tube Per Therapy Per Patient 72 tubes Consumed in Territory Converted In Boxes of 1's 72 tubes of Aplosyn 25 Ointment
reatment Months( from 72 Patients) x 1 tube Per Therapy Per Patient 72 tubes Consumed in Territory Converted In Boxes of 1's 72 tubes of Aplosyn 25 Ointment
PRESCRIPTION GENERATION MATRIX PER TERRITORY APLOSYN N (P128)

FY Treatments
48 44 40 36 32 28 24 20 16 12 8 4 312
200
8 12 12 12
12 24 24 24
16 40 40 40
20 60 60 60
24 84 84 84
28 112 112 112
32 144 144 144
36 180 180 180
40 220 220 220
44 264 264 264
48 312 312 312 34,944
Working objectives: 1. Two (2) out of 40 Target MD's shall respond with one( 1) APLOSYN N prescription every month 2. Four (4) new prescriptions shall be generated per month with patient consumption of 48tubes per month 3. Total MD output is equivalent to cumulative 312 new patient therapies the whole year 4. Rotating prescription output each month from at least one (1) out of 40 Target MD's for Aplosyn N 5. The condition is intermittent requiring new prescriptions for new patient therapy each month 6. Matrix calculation sums up to total of 1month therapies equivalent to 312 tubes consumption the whole year 48 Treatment Months( from 72 Patients) x 1 tube Per Therapy Per Patient 48 tubes Consumed in Territory Converted In Boxes of 1's 48 tubes of Aplosyn N
reatment Months( from 72 Patients) x 1 tube Per Therapy Per Patient 48 tubes Consumed in Territory Converted In Boxes of 1's
PRESCRIPTION GENERATION MATRIX PER TERRITORY ZILDEN (P68.00)x 10s

FY Treatments
36 33 30 27 24 21 18 15 12 9 6 3 234
205
Cum. equiv. new patients Equivalent 10 day therapy Equiv. cumulative tablets Equiv. cumulative. boxes
6 9 90 9
9 18 180 18
12 30 300 30
15 45 450 45
18 63 630 63
21 84 840 84
24 108 1,080 108
27 135 1,350 135
30 165 1,650 165
33 198 1,980 198
36 234 2,340 234 159,120.00
Working objectives: ERECTILE DYSFUNCTION 1. One (1) out of 40 Target MD's shall respond with one (1) ZILDEN Tablet prescription every month 2. Three (3) new prescriptions shall be generated per month with patient consumption of 10 tablets per therapy 3. Total MD output is equivalent to cumulative 36 new patient therapies the whole year 4. Rotating one prescription output each month from at least one (1) out of 40 Target MD's for Zilden Tablet 5. The condition is intermittent requiring new prescriptions for new patient therapy each month 6. Matrix calculation sums up to total of 324 therapies equivalent to 2,340 tablet consumption the whole year 234 therapies (from 36 Patients) x 10 Tablets Per Therapy Per Patient 2,340 Tablets Consumed in Territory Converted In Boxes of 10's 234 Boxes of Zilden Tabs
3 MDS = 1 RX @10 TABS QUADRANT 1 MD 1 MD 2 MD 3 Galindon, Greville II Cabreira, Alvin Trinidad, Timoteo QUADRANT 2 QUADRANT 3 QUADRANT 4
234 therapies (from 36 Patients)
Tablets Per Therapy Per Patient
ablets Consumed in Territory
PRESCRIPTION GENERATION MATRIX PER TERRITORY SENALAX (P6.50)x 20s

FY Treatments
288 264 240 216 192 168 144 120 96 72 48 24 1,872
1,648
48 72 720 24
72 144 1,440 48
96 240 2,400 80
120 360 3,600 120
144 504 5,040 168
168 672 6,720 224
192 864 8,640 288
216 1,080 10,800 360
240 1,320 13,200 440
264 1,584 15,840 528
288 1,872 18,720 624 81,120
Working objectives: CHRONIC CONSTIPATION 1. Four (4) out of 40 Target MD's shall respond with SIX (6) Senalax Tablets prescription every month 2. Six (6) new prescriptions shall be generated per month with patient consumption of 10 tablets per month 3. Total MD output is equivalent to cumulative 288 new patient therapies the whole year 4. Rotating prescription output each month from at least one (1) out of 40 Target MD's for Senalax Tablet 5. The condition is intermittent requiring new prescriptions for new patient therapy each month 6. Matrix calculation sums up to total of 156 seven day therapies equivalent to 1,872 tablet consumption the whole year 1872 seven day therapies (from 24 Patients) x 10 Tablets Per Therapy Per Patient 18,720 Tablets Consumed in Territory Converted In Boxes of 0's 936 Boxes of SENALAX Tablets
4 MD will RX 6 SENALAX @10 TABS PER THERAPY QUADRANT 1 MD 1 MD 2 MD 3 MD 4 MD 6 MD 7 MD 8 MD 9 MD 11 MD 12 MD 13 MD 14 Licup, Ronald Chuca, Leah Alvaro, May Castro, Abigail Go, Virginia Nogoy, Cecilia Bayani, Wilhelmina Liwanag, Martin Maglaya, Hermie Aragon, Helen Sanchez, Raul Gallinera, Ma. Cristina QUADRANT 2 QUADRANT 3 QUADRANT 4
from 24 Patients)
erapy Per Patient
med in Territory
ENALAX Tablets
PRESCRIPTION GENERATION MATRIX PER TERRITORY NEVRAMIN(P11.95)x 30s

FY Treatments
12 11 10 9 8 7 6 5 4 3 2 1 78
MD 1 MD2 23
2 3 90 3
3 6 180 6
4 10 300 10
5 15 450 15
6 21 630 21
7 28 840 28
8 36 1,080 36
9 45 1,350 45
10 55 1,650 55
11 66 1,980 66
12 78 2,340 78 27,963
Working objectives: NEURITIS 1. One (1) out of 40 Target MD's shall respond with ONE (1) NEVRAMIN Tablet prescription every month 2. One (1) new prescriptions shall be generated per month with patient consumption of 30 tablets per month 3. Total MD output is equivalent to cumulative 1 new patient therapies the whole year 4. Rotating prescription output each month from at least one (1) out of 40 Target MD's for NevraminTablet 5. The condition is intermittent requiring new prescriptions for new patient therapy each month 6. Matrix calculation sums up to total of 78 seven day therapies equivalent to 2,340 tablet consumption the whole year 78 therapies (from 12 Patients) x 30 Tablets Per Therapy Per Patient 2,340 Tablets Consumed in Territory Converted In Boxes of 30's 78 Boxes of Nevramin Tablets
1 MD = 1 RX @30 TABS QUADRANT 1 Aragon, Helen Vega, Rowena QUADRANT 2 QUADRANT 3 QUADRANT 4
78 therapies (from 12 Patients) x 30 Tablets Per Therapy Per Patient
,340 Tablets Consumed in Territory Converted In Boxes of 30's 78 Boxes of Nevramin Tablets

FY Treatments
120 110 100 90 80 70 60 50 40 30 20 10 780
MD 1 MD 2
693
20 30 900 30
30 60 1,800 60
40 100 3,000 100
50 150 4,500 150
60 210 6,300 210
70 280 8,400 280
80 360 10,800 360
90 450 13,500 450
100 550 16,500 550
110 660 19,800 660
120 780 23,400 780 279,630
Working objectives: NEURITIS 1. Five (5) out of 40 Target MD's shall respond with ONE (2) NEVRAMIN Tablet prescription every month 2. Two (2) new prescriptions shall be generated per month with patient consumption of 30 tablets per month 3. Total MD output is equivalent to cumulative 1 new patient therapies the whole year 4. Rotating prescription output each month from at least five (5) out of 40 Target MD's for NevraminTablet 5. The condition is intermittent requiring new prescriptions for new patient therapy each month 6. Matrix calculation sums up to total of 780 seven day therapies equivalent to 23,400 tablet consumption the whole year 780 therapies (from 12 Patients) x 30 Tablets Per Therapy Per Patient 23,400 Tablets Consumed in Territory Converted In Boxes of 30's 780 Boxes of Nevramin Tablets
1 MD = 2 RX @30 TABS QUADRANT 1 QUADRANT 2 QUADRANT 3 Maglaya, Hermie Bustamente, Lara Marie QUADRANT 4

FY Treatments
12 11 10 9 8 7 6 5 4 3 2 1 78
MD 1 MD2 5
2 3 90 3
3 6 180 6
4 10 300 10
5 15 450 15
6 21 630 21
7 28 840 28
8 36 1,080 36
9 45 1,350 45
10 55 1,650 55
11 66 1,980 66
12 78 2,340 78 27,963
Working objectives: NEURITIS 1. One (1) out of 40 Target MD's shall respond with ONE (1) NEVRAMIN Tablet prescription every month 2. One (1) new prescriptions shall be generated per month with patient consumption of 30 tablets per month 3. Total MD output is equivalent to cumulative 1 new patient therapies the whole year 4. Rotating prescription output each month from at least one (1) out of 40 Target MD's for NevraminTablet 5. The condition is intermittent requiring new prescriptions for new patient therapy each month 6. Matrix calculation sums up to total of 78 seven day therapies equivalent to 2,340 tablet consumption the whole year 78 therapies (from 12 Patients) x 30 Tablets Per Therapy Per Patient 2,340 Tablets Consumed in Territory Converted In Boxes of 30's 78 Boxes of Nevramin Tablets
1 MD = 1 RX @30 TABS QUADRANT 1 Nogoy, Cecilia Toy, Visitacion QUADRANT 2 QUADRANT 3 QUADRANT 4

Target Formulation Per SKU&#39;s

Diunggah oleh

Informasi Dokumen

Hak Cipta

Format Tersedia

Bagikan dokumen Ini

Bagikan atau Tanam Dokumen

Opsi Berbagi

Apakah menurut Anda dokumen ini bermanfaat?

Apakah konten ini tidak pantas?

Hak Cipta:

Format Tersedia

Target Formulation Per SKU&#39;s

Diunggah oleh

Hak Cipta:

Format Tersedia

PRESCRIPTION GENERATION MATRIX PER TERRITORY RELEAF TAB (P4.

12 78 14,040 140 58,968.00

4,040 Tablets Consumed in Territory Converted In Boxes of 100's

40 Boxes of RELEAF 250 MG Tablets

PRESCRIPTION GENERATION MATRIX PER TERRITORY RELEAF FORTE(P7.25)

45 135 24,300 405

54 189 34,020 567

63 252 45,360 756

72 324 58,320 972

81 405 72,900 1,215

90 495 89,100 1,485

99 594 106,920 1,782

108 702 126,360 2,106

BAYANI, WILHELMINA CURAMMENG, LOUISE DOMINGO, ARIEL

6,360 Tablets Consumed in Territory Converted In Boxes of 60's

06 Boxes of RELEAF 500 MG Tablets

PRESCRIPTION GENERATION MATRIX PER TERRITORY APLOSYN 10 Cream 5MG (P112)

36 126 126 126

42 168 168 168

48 216 216 216

54 270 270 270

60 330 330 330

66 396 396 396

72 468 468 468 52,416

reatment Months( from 81 Patients) x 1 tube Per Therapy Per Patient

PRESCRIPTION GENERATION MATRIX PER TERRITORY APLOSYN 10 Ointment 5MG (P112)

36 126 126 126

42 168 168 168

48 216 216 216

54 270 270 270

60 330 330 330

66 396 396 396

72 468 468 468 52,416

reatment Months( from 81 Patients) x 1 tube Per Therapy Per Patient

468 tubes Consumed in Territory Converted In Boxes of 1's

468 tubes of Aplosyn 10 ointment

PRESCRIPTION GENERATION MATRIX PER TERRITORY APLOSYN 10-N CREAM (P124)

36 126 126 126

42 168 168 168

48 216 216 216

54 270 270 270

60 330 330 330

66 396 396 396

72 468 468 468 52,416

reatment Months( from 81 Patients) x 1 tube Per Therapy Per Patient

PRESCRIPTION GENERATION MATRIX PER TERRITORY APLOSYN 25 CREAM (P124)

20 110 110 110

22 132 132 132

24 157 157 157 17,584

reatment Months( from 24 Patients) x 1 tube Per Therapy Per Patient

PRESCRIPTION GENERATION MATRIX PER TERRITORY APLOSYN 25 Ointment(P124)

36 126 126 126

42 168 168 168

48 216 216 216

54 270 270 270

60 330 330 330

66 396 396 396

72 468 468 468 52,416

PRESCRIPTION GENERATION MATRIX PER TERRITORY APLOSYN N (P128)

28 112 112 112

32 144 144 144

36 180 180 180

40 220 220 220

44 264 264 264

Target Formulation Per SKU's

Target Formulation Per SKU's